ID   HPB-ALL
AC   CVCL_1820
SY   HPB/ALL; HPBALL; FCCH1018
DR   BTO; BTO:0001952
DR   CLO; CLO_0003817
DR   CLO; CLO_0050988
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN01821632
DR   BioSample; SAMN03473562
DR   BioSample; SAMN10988462
DR   cancercelllines; CVCL_1820
DR   Cell_Model_Passport; SIDM01618
DR   ChEMBL-Cells; CHEMBL4295419
DR   ChEMBL-Targets; CHEMBL4296435
DR   Cosmic; 801726
DR   Cosmic; 913406
DR   Cosmic; 919159
DR   Cosmic; 933550
DR   Cosmic; 998736
DR   Cosmic; 999754
DR   Cosmic; 1037689
DR   Cosmic; 1115583
DR   Cosmic; 1130235
DR   Cosmic; 1151779
DR   Cosmic; 1224373
DR   Cosmic; 1281368
DR   Cosmic; 1330499
DR   Cosmic; 1524796
DR   Cosmic; 1641378
DR   Cosmic; 1664521
DR   Cosmic; 1760522
DR   Cosmic; 2165711
DR   Cosmic; 2602914
DR   DepMap; ACH-000942
DR   DSMZ; ACC-483
DR   DSMZCellDive; ACC-483
DR   GEO; GSM887091
DR   GEO; GSM888162
DR   GEO; GSM5137717
DR   IARC_TP53; 21703
DR   LiGeA; CCLE_898
DR   Lonza; 250
DR   NCBI_Iran; C213
DR   PharmacoDB; HPBALL_566_2019
DR   PRIDE; PXD023662
DR   Progenetix; CVCL_1820
DR   PubChem_Cell_line; CVCL_1820
DR   RCB; RCB1935
DR   TKG; TKG 0199
DR   Wikidata; Q54890235
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=203546;
RX   PubMed=1373528;
RX   PubMed=2140233;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=6181032;
RX   PubMed=6582512;
RX   PubMed=6749281;
RX   PubMed=8127147;
RX   PubMed=8641406;
RX   PubMed=8957066;
RX   PubMed=9510473;
RX   PubMed=9738977;
RX   PubMed=9933131;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=12661009;
RX   PubMed=15472075;
RX   PubMed=16142349;
RX   PubMed=17170727;
RX   PubMed=22460905;
RX   PubMed=22675565;
RX   PubMed=26589293;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=35354797;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-55.html
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Doubling time: ~50 hours (DSMZ=ACC-483).
CC   HLA typing: A*24:02,24:02; B*15:07,52:01; C*03:03,12:02 (PubMed=26589293).
CC   HLA typing: A*24:02:01,24:02:01; B*15:07:01,52:01:01; C*03:03:01,12:02:02 (DSMZCellDive=ACC-483).
CC   Microsatellite instability: Instable (MSI) (PubMed=10739008; PubMed=11226526; PubMed=31068700).
CC   Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 29824; MYL11; Name(s)=CBFB-MYL11, CBFB-MYLPF (PubMed=31160637).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465His (c.1394G>A); ClinVar=VCV000376415; Zygosity=Unspecified (PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Ala134Ser (c.400G>T); Zygosity=Unspecified (PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1574Pro (c.4721T>C); Zygosity=Heterozygous (PubMed=15472075).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp2442fs*39 (c.7326_7326insGGGCCGTGGACG); Zygosity=Heterozygous (PubMed=15472075).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg159Ser (c.477G>T); ClinVar=VCV000375959; Zygosity=Unspecified (PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys124Ter (c.372C>A); ClinVar=VCV000458537; Zygosity=Homozygous (PubMed=16142349; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Ser121Ter (c.362C>A); Zygosity=Unspecified (PubMed=22675565).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=78.04%; East Asian, South=20.81%; South Asian=1.14%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): DSMZ; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,10
ST   D16S539: 9,11
ST   D18S51: 15,19
ST   D19S433: 13,14
ST   D21S11: 30
ST   D2S1338: 21
ST   D3S1358: 17
ST   D5S818: 11
ST   D7S820: 11
ST   D8S1179: 11,12
ST   FGA: 19,23
ST   Penta D: 9,11
ST   Penta E: 10,15
ST   TH01: 7,9
ST   TPOX: 8,12
ST   vWA: 18,20
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 35
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=203546; DOI=10.1002/ijc.2910210207;
RA   Morikawa S., Tatsumi E., Baba M., Harada T., Yasuhira K.;
RT   "Two E-rosette-forming lymphoid cell lines.";
RL   Int. J. Cancer 21:166-170(1978).
//
RX   PubMed=1373528;
RA   Duan D.-S., Smith W., Sadee W., Cowan M.J.;
RT   "Characterization of three T-lymphoid cell lines with distinct
RT   sensitivities to deoxyadenosine plus deoxycoformycin.";
RL   Thymus 19:1-11(1992).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=6181032; DOI=10.1016/0198-8859(82)90037-4;
RA   Rabinowitz R., Weinstock J., Margalioth E.J., Ben-Bassat H.,
RA   Schlesinger M.;
RT   "Antigens specific for human T-lymphocytes detected by xenoantisera to
RT   HD-MAR cells: their differential expression on various T-cell lines.";
RL   Hum. Immunol. 4:219-228(1982).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6749281; DOI=10.1002/1097-0142(19821101)50:9<1775::AID-CNCR2820500922>3.0.CO;2-T;
RA   Kanazawa S., Morikawa S., Harada T., Yasuhira K., Matsubara Y.,
RA   Ikeda S., Soeda S., Fujimura M.;
RT   "Carcinoembryonic antigen producing cultured cell lines enable
RT   detection of autoantibodies in sera from patients with
RT   gastrointestinal cancer.";
RL   Cancer 50:1775-1782(1982).
//
RX   PubMed=8127147;
RA   Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y.,
RA   Xu B., Einhorn S.;
RT   "Interferon system defects in malignant T-cells.";
RL   Leukemia 8:425-434(1994).
//
RX   PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x;
RA   Borgonovo-Brandter L., Heyman M., Rasool O., Liu Y., Grander D.,
RA   Einhorn S.;
RT   "p16INK4/p15INK4B gene inactivation is a frequent event in malignant
RT   T-cell lines.";
RL   Eur. J. Haematol. 56:313-318(1996).
//
RX   PubMed=8957066; DOI=10.1111/j.1349-7006.1996.tb03112.x;
RA   Kawasaki N., Matsuo Y., Yoshino T., Yanai H., Oka T., Teramoto N.,
RA   Liu C., Kondo E., Minowada J., Akagi T.;
RT   "Metastatic potential of lymphoma/leukemia cell lines in SCID mice is
RT   closely related to expression of CD44.";
RL   Jpn. J. Cancer Res. 87:1070-1077(1996).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=9933131; DOI=10.1016/S0145-2126(98)00133-7;
RA   Burger R., Hansen-Hagge T.E., Drexler H.G., Gramatzki M.;
RT   "Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines:
RT   suggestion for classification by immunophenotype and T-cell receptor
RT   studies.";
RL   Leuk. Res. 23:19-27(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=12661009; DOI=10.1002/gcc.10194;
RA   MacLeod R.A.F., Nagel S., Kaufmann M., Janssen J.W.G., Drexler H.G.;
RT   "Activation of HOX11L2 by juxtaposition with 3'-BCL11B in an acute
RT   lymphoblastic leukemia cell line (HPB-ALL) with t(5;14)(q35;q32.2).";
RL   Genes Chromosomes Cancer 37:84-91(2003).
//
RX   PubMed=15472075; DOI=10.1126/science.1102160;
RA   Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B.,
RA   Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.;
RT   "Activating mutations of NOTCH1 in human T cell acute lymphoblastic
RT   leukemia.";
RL   Science 306:269-271(2004).
//
RX   PubMed=16142349; DOI=10.3892/or.14.4.901;
RA   Smardova J., Pavlova S., Svitakova M., Grochova D., Ravcukova B.;
RT   "Analysis of p53 status in human cell lines using a functional assay
RT   in yeast: detection of new non-sense p53 mutation in codon 124.";
RL   Oncol. Rep. 14:901-907(2005).
//
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   de Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22675565; DOI=10.1371/journal.pone.0038463;
RA   Atak Z.K., De Keersmaecker K., Gianfelici V., Geerdens E.,
RA   Vandepoel R., Pauwels D., Porcu M., Lahortiga I., Brys V., Dirks W.G.,
RA   Quentmeier H., Cloos J., Cuppens H., Uyttebroeck A., Vandenberghe P.,
RA   Cools J., Aerts S.;
RT   "High accuracy mutation detection in leukemia on a selected panel of
RT   cancer genes.";
RL   PLoS ONE 7:E38463-E38463(2012).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//